{"id":3434,"text":"Increasing use of medicinal herbs as nutritional supplements and traditional medicines for the treatment of diabetes, hypertension, hyperlipidemia, and malaria fever with conventional drugs poses possibilities of herb–drug interactions ( In vitro inhibition of eight major   Mangifera indica moderately inhibited  Potential for clinically important     Funding information  This research did not receive any specific grant from funding agencies in the public, commercial, or not‐for‐profit sectors Management of chronic diseases is burdensome to patients (Eton et al., 2013; Ørtenblad, Meillier, & Jønsson, 2017) who tend to seek alternative remedies to conventional medications that may supposedly provide cure or offer safe use (Yarney et al., 2013; Joeliantina, Agil, Qomaruddin, Jonosewojo, & Kusnanto, 2016) This self‐medication practice is common among chronically ill patients or patients with terminal diseases (Bodenheimer, Lorig, Holman, & Grumbach, 2002; Hasan, Ahmed, Bukhari, & Loon, 2009), and the major culprit in this group of patients are dietary supplements and herbal medicines (Gardiner, Graham, Legedza, Eisenberg, & Phillips, 2006; Gardiner, Phillips, & Shaughnessy, 2008).","label":[[108,116,"Pathology"],[118,130,"Pathology"],[132,146,"Pathology"],[152,165,"Pathology"],[238,246,"Study"],[275,291,"Herb name"]],"Comments":[]}
{"id":3435,"text":"The perceived believe of cure and safety of these agents makes ambulatory patients take them without due recourse to their physician (Mehta, Gardiner, Phillips, & McCarthy, 2008; Zhang, Onakpoya, Posadzki, & Eddouks, 2015).","label":[],"Comments":[]}
{"id":3436,"text":"In various settings, about 40%–57% of patients fail to disclose herbs used concomitantly with their medications to the physician (Robinson & McGrail, 2004; Fakeye, Tijani, & Adebisi, 2008; Kennedy, Wang, & Wu, 2008).","label":[],"Comments":[]}
{"id":3437,"text":"Some of these herbs especially in sub‐Saharan Africa, India, and in some other parts of the world are consumed as seasoning agents (garlic—Allium sativum), vegetables (Gongronema latifolium and Moringa oleifera), and as edible fruits and seeds (Musa sapientum, Mangifera indica, and Tetracarpidium conophorum).","label":[[132,153,"Herb name"],[168,189,"Herb name"],[194,210,"Herb name"],[227,233,"Herb part"],[238,243,"Herb part"],[245,259,"Herb name"],[261,277,"Herb name"],[283,308,"Herb name"]],"Comments":[]}
{"id":3438,"text":"Patients who are on medications and consumes these medicinal herbs may not be aware of potential herb–drug interactions (HDIs) that may occur.","label":[],"Comments":[]}
{"id":3439,"text":"Others such as Alstonia boonei, Bauhinia monandra, and Picralima nitida are frequently used in sub‐Saharan Africa and India in the management of chronic diseases such as hypertension, diabetes, asthma, peptic ulcer, and cancer, as antimalarials and antimicrobials and other minor ailments (Mahomoodally, 2013; Ezuruike & Prieto, 2014; Iwu, 2014).","label":[[15,30,"Herb name"],[32,49,"Herb name"],[55,71,"Herb name"],[170,182,"Pathology"],[184,192,"Pathology"],[194,200,"Pathology"],[202,214,"Pathology"],[220,226,"Pathology"]],"Comments":[]}
{"id":3440,"text":"Sometimes, in the treatment of these diseases, herbs may be used singly or in combination and prepared as dried powder or decoction.","label":[[106,118,"Extraction process"],[122,131,"Extraction process"]],"Comments":[]}
{"id":3441,"text":"There are many examples of such practice.","label":[],"Comments":[]}
{"id":3442,"text":"For example, for rheumatism, bark of Picralima nitida, leaves of Allium ascalonicum, Calliandra portoricensis, and Xylopia aethiopica are grounded, cooked, and 15 ml of the mixture is mixed with corn pap and taken once daily (Olorunnisola, Adetutu, & Afolayan, 2015).","label":[[17,27,"Pathology"],[29,33,"Herb part"],[37,53,"Herb name"],[55,61,"Herb part"],[65,83,"Herb name"],[85,109,"Herb name"],[115,133,"Herb name"],[195,199,"Herb name"],[200,203,"Extraction process"]],"Comments":[]}
{"id":3443,"text":"For anemia, a mixture of the bark of Mangifera indica and fruits of Aframomum melequeta is dried and powdered with one tablespoonful administered daily (Gbadamosi, Moody, & OYekini, 2012).","label":[[4,10,"Pathology"],[29,33,"Herb part"],[37,53,"Herb name"],[58,64,"Herb part"],[68,87,"Herb name"],[91,109,"Extraction process"],[146,151,"Frequency"]],"Comments":[]}
{"id":3444,"text":"A decoction of dried bark of Alstonia boonei is also taken two‐ to three times daily by diabetic patients to lower blood glucose (Adotey, Adukpo, Opoku Boahen, & Armah, 2012).","label":[[2,20,"Extraction process"],[21,25,"Herb part"],[29,44,"Herb name"],[59,84,"Frequency"],[88,96,"Pathology"],[115,128,"Parameter"]],"Comments":[]}
{"id":3445,"text":"Many diseases are usually managed or treated with conventional medicines which are mostly metabolized by cytochrome P450 (CYP) isoenzymes (Rendic & Guengerich, 2014).","label":[[105,137,"Target"]],"Comments":[]}
{"id":3446,"text":"These isoenzymes are responsible for the metabolism of over 70% of prescription and over‐the‐counter medications (Rendic & Guengerich, 2014).","label":[],"Comments":[]}
{"id":3447,"text":"Concomitantly administered drug may modulate these CYP isoenzymes activities leading to clinically significant drug–drug interactions.","label":[[51,65,"Target"]],"Comments":[]}
{"id":3448,"text":"Such interaction may result in serious adverse drug reactions requiring hospitalization, especially drugs with narrow therapeutic index such as carbamazepine, theophylline, digoxin warfarin, and phenytoin (Greenblatt & von Moltke, 2005; Perucca, 2006; de Leon, 2007; Patel, Rana, Suthar, Malhotra, & Patel, 2014).","label":[[39,61,"Pathology"],[144,157,"Drug"],[159,171,"Drug"],[173,180,"Drug"],[181,189,"Drug"],[195,204,"Drug"]],"Comments":[]}
{"id":3449,"text":"It is thus rational to expect herbs to also elicit similar HDIs via modulation of cytochrome P450 isoenzymes when concomitantly administered with conventional drugs.","label":[[82,108,"Target"]],"Comments":[]}
{"id":3450,"text":"Herbs contain bioactive secondary metabolites such as anthocyanins, flavonoid, tannins, saponins, alkaloids, and cardenolides, some of which have been shown to inhibit the activity of CYP isoenzymes (Henderson, Miranda, Stevens, Deinzer, & Buhler, 2000; Dreiseitel et al., 2008; Kimura, Ito, Ohnishi, & Hatano, 2010; Sand et al., 2010).","label":[[54,66,"Herb name"],[68,77,"Herb name"],[79,86,"Herb name"],[88,96,"Herb name"],[98,107,"Herb name"],[113,125,"Herb name"],[184,198,"Target"]],"Comments":[]}
{"id":3451,"text":"Several studies have documented the occurrence of serious adverse events as a result of concurrent administration of herbs and drugs.","label":[[58,72,"Pathology"]],"Comments":[]}
{"id":3452,"text":"Such interactions included bleeding experienced with coadministration of Allium sativum and nonsteroidal anti‐inflammatory drugs (Fugh‐Berman, 2000), manic episode with Panax ginseng and phenelzine (Fugh‐Berman, 2000), and fatal seizure with concomitant administration of Ginkgo biloba and valproate (Kupiec & Raj, 2005).","label":[[27,35,"Pathology"],[73,87,"Herb name"],[92,128,"Drug"],[150,163,"Pathology"],[169,182,"Herb name"],[187,197,"Drug"],[229,236,"Pathology"],[272,285,"Herb name"],[290,299,"Drug"]],"Comments":[]}
{"id":3453,"text":"Several herbs such as St. John's wort, grapefruit juice, Ginkgo biloba, black pepper, and Echinacea are known inhibitors of CYP 2C9, 2C19, 2E1, and 3A4 (Wang et al., 2001; Gorski et al., 2004; Mohutsky, Anderson, Miller, & Elmer, 2006; Sukkasem & Jarukamjorn, 2016).","label":[[22,37,"Herb name"],[39,49,"Herb name"],[39,55,"Extraction process"],[57,70,"Herb name"],[72,84,"Herb name"],[90,99,"Herb name"],[124,151,"Target"]],"Comments":[]}
{"id":3454,"text":"Little is known of the effect of most tropical medicinal herbs on the metabolic capacity of CYP isoenzymes.","label":[[92,106,"Target"]],"Comments":[]}
{"id":3455,"text":"The possibility of occurrence of HDIs when herbs are consumed as seasoning agents, vegetables, fruits and as herbal medicines with conventional drugs informed this study.","label":[],"Comments":[]}
{"id":3456,"text":"Since inhibition of CYP isoenzymes is the first step toward elucidating potential HDIs, this study evaluated nine widely used tropical medicinal herbs with a view to identifying those with potentials for CYP‐metabolism‐mediated HDIs.","label":[[20,34,"Target"],[204,207,"Target"]],"Comments":[]}
{"id":3457,"text":"Some of the herbs considered in this study have also been shown to inhibit CYP isoenzymes.","label":[[75,89,"Target"]],"Comments":[]}
{"id":3458,"text":"Allium sativum inhibits CYP 2C9, 2C19, 2D6, 3A4\/5, and 3A7 (Foster et al., 2001; Greenblatt, Leigh‐Pemberton, & von Moltke, 2006; Engdal & Nilsen, 2009); Moringa oleifera—CYP 1A2, 3A4, and 2D6 (Monera, Wolfe, Maponga, Benet, & Guglielmo, 2008; Taesotikul, Navinpipatana, & Tassaneeyakul, 2010; Ahmmed et al., 2015; Awortwe, 2015); Musa sapientum—CYP 1A2 and 3A11 (Chatuphonprasert & Jarukamjorn, 2012) while Mangifera indica has been shown to inhibit CYP 1A2, 2C9, 2C19, 2D6, 3A4, and 3A11 (Chatuphonprasert & Jarukamjorn, 2012).","label":[[0,14,"Herb name"],[24,58,"Target"],[154,170,"Herb name"],[171,192,"Target"],[331,345,"Herb name"],[346,362,"Target"],[408,424,"Herb name"],[451,489,"Target"]],"Comments":[]}
{"id":3459,"text":"In the above studies, different enzyme sources, probe substrates, and extraction methods were employed in evaluating one to five CYP isoenzyme inhibition profiles of the stated herbs which do not represent the full complement of major human CYP isoenzymes.","label":[[129,142,"Target"],[241,255,"Target"]],"Comments":[]}
{"id":3460,"text":"The present study improved on this by mimicking local methods of preparation of plant extracts, used pooled human liver microsomes containing eight major CYP isoenzymes responsible for over 70% metabolism of drugs (Rendic & Guengerich, 2014), and nine probe substrates with N‐in‐one cocktail method to profile the inhibitory potentials of the herbs on CYP isoenzymes.","label":[[154,168,"Target"],[352,366,"Target"]],"Comments":[]}
{"id":3461,"text":"Nine medicinal herbs widely used in the tropics for the management of chronic diseases such as hypertension, diabetes, dyslipidemia, chronic kidney disease were selected for this study with the plant parts used and listed in Table 1.","label":[[95,107,"Pathology"],[109,117,"Pathology"],[119,131,"Pathology"],[133,155,"Pathology"]],"Comments":[]}
{"id":3462,"text":"Plant parts used were sourced from open market and herb vendors.","label":[],"Comments":[]}
{"id":3463,"text":"Some were identified and authenticated at the Department of Pharmacognosy, University of Ibadan with voucher numbers DPHUI 1385, DPHUI 1386, DPHUI 1387, DPHUI 1388, and DPHUI 1624 for Alstonia boonei, Mangifera indica, Musa sapientum, Bauhinia monandra, and Moringa oleifera leaves, respectively.","label":[[184,199,"Herb name"],[201,217,"Herb name"],[219,233,"Herb name"],[235,252,"Herb name"],[258,274,"Herb name"],[275,281,"Herb part"]],"Comments":[]}
{"id":3464,"text":"Other plants parts such as Tetracarpidium conophorum seeds, Picralima nitida seed, Allium sativum bulb, and Gongronema latifolium leaves were collected and identified at Forestery Research Institute of Nigeria with voucher numbers No.","label":[[27,52,"Herb name"],[53,58,"Herb part"],[60,76,"Herb name"],[77,81,"Herb part"],[83,97,"Herb name"],[98,102,"Herb part"],[108,129,"Herb name"],[130,136,"Herb part"]],"Comments":[]}
{"id":3465,"text":"FHI110276, FHI210232, FHI210233, and FHI210234, respectively.","label":[],"Comments":[]}
{"id":3466,"text":"Plant parts were chopped into smaller bits and dried in the oven (Gallenhamp oven, Cat number GVH 500.010 G. Germany) separately at 40°C for 24–48 hr until a constant weight was obtained.","label":[],"Comments":[]}
{"id":3467,"text":"Thereafter, each plant part was blended with Kenwood blender (model number: OWBL436003, China) for 3 min.","label":[],"Comments":[]}
{"id":3468,"text":"Detail of medicinal herbs used in the screening of potential inhibition of cytochrome P450 isoenzymes I, Igbo; Y, Yoruba; H, Hausa.","label":[[75,101,"Target"]],"Comments":[]}
{"id":3469,"text":"Three hundred gram each of dried and powdered Alstonia boonei stem bark, Mangifera indica stem bark, Musa sapientum unriped fruits, Bauhinia monandra leaves, Tetracarpidium conophorum seeds, Allium sativum bulb, and Gongronema latifolium leaves were macerated in 1.5 L of distilled water for 24 hr according to extraction procedure practiced locally by users of these herbs.","label":[[27,45,"Extraction process"],[46,61,"Herb name"],[62,71,"Herb part"],[73,89,"Herb name"],[90,99,"Herb part"],[101,115,"Herb name"],[116,130,"Herb part"],[132,149,"Herb name"],[150,156,"Herb part"],[158,183,"Herb name"],[184,189,"Herb part"],[191,205,"Herb name"],[206,210,"Herb part"],[216,237,"Herb name"],[238,244,"Herb part"]],"Comments":[]}
{"id":3470,"text":"Dry powdered Moringa oleifera leaves (50 g) and powdered dry Picralima nitida seeds (70 g) were each macerated in 300 ml of distilled water.","label":[[0,12,"Extraction process"],[13,29,"Herb name"],[30,36,"Herb part"],[48,60,"Extraction process"],[61,77,"Herb name"],[78,83,"Herb part"],[101,110,"Extraction process"]],"Comments":[]}
{"id":3471,"text":"Each mixture was filtered, concentrated, and freeze‐dried.","label":[],"Comments":[]}
{"id":3472,"text":"The freeze‐dried extracts were stored at −20°C until needed for in vitro analysis.","label":[[4,25,"Extraction process"],[64,81,"Study"]],"Comments":[]}
{"id":3473,"text":"Acetic acid and HPLC‐grade acetonitrile were purchased from Merck (LiChrosolv GG, Darmstadt, Germany).","label":[],"Comments":[]}
{"id":3474,"text":"Hydroxydiclofenac, desmethylomeprazole, 3‐hydroxyomeprazole, and hydroxycoumarin were obtained from Sigma‐Aldrich, St Louis, USA; 6‐hydroxytestosterone, dextrorphan, and desethylamodiaquine form BD Biosciences Discovery Labware, Bedford, USA; 5‐hydroxyomeprazole and omeprazole sulfone from Astra Zeneca, M¨olndal, Sweden; 1‐hydroxymidazolam from F. Hoffmann‐La Roche, Basel, Switzerland; phenacetin from ICN Biomedicals, Costa Mesa, USA.","label":[[0,17,"Drug"],[19,38,"Drug"],[40,59,"Drug"],[65,80,"Drug"],[130,151,"Drug"],[153,164,"Drug"],[170,189,"Drug"],[243,262,"Drug"],[267,277,"Drug"],[323,341,"Drug"],[389,399,"Drug"]],"Comments":[]}
{"id":3475,"text":"Hydroxybupropion was a free gift from Glaxo SmithKline Research Triangle, NC.","label":[[0,16,"Drug"]],"Comments":[]}
{"id":3476,"text":"Water used was purified by Simplicity 185 water purifier (Millipore, Molsheim, France).","label":[],"Comments":[]}
{"id":3477,"text":"All other chemicals and reagents were of analytical grade.","label":[],"Comments":[]}
{"id":3478,"text":"Human liver microsomes were obtained from a pool of liver samples from 25 male and female donors and contain 20 mg protein\/ ml (Lot No: 99268 from BD Biosciences Labware, Bedford, MA).","label":[[71,89,"Cohort"],[74,78,"Sex"],[83,89,"Sex"]],"Comments":[]}
{"id":3479,"text":"This was used for the metabolite profiling and CYP inhibition study.","label":[[47,50,"Target"],[47,67,"Study"]],"Comments":[]}
{"id":3480,"text":"N‐in‐one approach (cocktail‐approach) for elucidating inhibition toward CYP‐specific model reactions was conducted with minor changes as described in earlier studies (Turpeinen, Jouko, Jorma, & Olavi, 2005; Tolonen, Petsalo, Turpeinen, Uusitalo, & Pelkonen, 2007; Showande, Fakeye, Ari, & Hokkanen, 2013).","label":[[72,75,"Target"]],"Comments":[]}
{"id":3481,"text":"Briefly, the incubation mixture was made up of 0.3 mg microsomal protein\/ml, 0.1 M phosphate buffer (pH 7.4), 1 mM NADPH, and nine probe substrates representing the major drug‐metabolizing CYPs.","label":[[115,120,"Target"],[189,193,"Target"]],"Comments":[]}
{"id":3482,"text":"The specific probe substrate used for each CYP isoenzymes studied and the respective final concentration in the incubation mixture were as follows: acetaminophen (CYP1A2, 10 μM), coumarin (CYP2A6, 2 μM), bupropion (CYP2B6, 2 μM), repaglinide (CYP2C8, 5 μM), diclofenac (CYP2C9, 5 μM), omeprazole (CYP2C19 and CYP3A4, 5 μM), dextromethorphan (CYP2D6, 1 μM), midazolam (CYP3A4, 1 μM), and testosterone (CYP3A4, 5 μM).","label":[[43,65,"Study"],[148,161,"Drug"],[163,169,"Target"],[179,187,"Drug"],[189,195,"Target"],[204,213,"Drug"],[215,221,"Target"],[230,241,"Drug"],[243,249,"Target"],[258,268,"Drug"],[270,276,"Target"],[285,295,"Drug"],[297,304,"Target"],[309,315,"Target"],[324,340,"Drug"],[342,348,"Target"],[357,366,"Drug"],[368,374,"Target"],[387,399,"Target"],[401,407,"Target"]],"Comments":[]}
{"id":3483,"text":"Each freeze‐dried aqueous herb extract was dissolved into methanol and added to the incubation mixture to obtain final concentrations of 0.001, 0.01, 0.1, 1, 10, 100, and 1000 μg\/ml.","label":[[5,38,"Extraction process"]],"Comments":[]}
{"id":3484,"text":"The resulting reaction mixture (200 μl) contains 1% (v\/v) methanol.","label":[],"Comments":[]}
{"id":3485,"text":"This was preincubated in a shaking incubator block (Eppendorf Thermomixer 5436, Hamburg, Germany) for 6 min at 37°C prior to the initiation of the reaction with the addition of NADPH.","label":[[177,182,"Target"]],"Comments":[]}
{"id":3486,"text":"Each reaction mixture containing different herb extracts or solvent control and other components was stopped after a period of 15 min by adding 200 μl of ice‐cold acetonitrile.","label":[],"Comments":[]}
{"id":3487,"text":"Proteins were precipitated from the sample by cooling it in an ice bath.","label":[],"Comments":[]}
{"id":3488,"text":"Supernatants collected from the samples were then stored at −20°C until analyzed.","label":[],"Comments":[]}
{"id":3489,"text":"Prior to analysis, all incubation samples were thawed at room temperature, votex‐mixed, and centrifuged for 10 min at 10000 g. The experiments were performed in duplicate.","label":[],"Comments":[]}
{"id":3490,"text":"The validated parameters for the methods were adequate for quantification ranges < 1%–300% of the forming metabolite concentrations with LOD 0.2–10 nM, accuracies 85%–115%, and precisions <15% at all concentrations, and with good autosampler stability (>95%) up to 48 hr.","label":[],"Comments":[]}
{"id":3491,"text":"Positive controls (see Supporting Information data, Table S1), CYP isoenzymes inhibited, and concentration used in the N‐in‐one assay are as reported in the validated methods (Turpeinen et al., 2005; Tolonen et al., 2007; Showande et al., 2013).","label":[[63,77,"Target"]],"Comments":[]}
{"id":3492,"text":"Spiked standard samples were not used for quantification of probe metabolites, but quantification based on relative peak areas was used (solvent control = 100%).","label":[],"Comments":[]}
{"id":3493,"text":"The analysis of probe metabolites from CYP‐specific marker reactions was conducted with a LC\/MS\/MS method modified from earlier works (Turpeinen et al., 2005; Tolonen et al., 2007) and also reported by (Showande et al., 2013).","label":[[39,42,"Target"]],"Comments":[]}
{"id":3494,"text":"Briefly, a Waters Acquity UPLC system (Waters Corp., Milford, MA) was used together with a Waters HSS C18 column (2.1 mm × 50 mm; 1.8 μm particle size) and an online filter at 35°C.","label":[],"Comments":[]}
{"id":3495,"text":"The injection volume was 4 μl, and UPLC eluents were aqueous 0.1% acetic acid (pH 3.2, A) and acetonitrile (B).","label":[],"Comments":[]}
{"id":3496,"text":"The gradient elution from 2%–65%–95% B was applied in 0–2.5–3.5 min, followed by column equilibration, giving a total time of 4.5 min\/injection.","label":[],"Comments":[]}
{"id":3497,"text":"The eluent flow rate was 0.5 ml\/min.","label":[],"Comments":[]}
{"id":3498,"text":"Data were acquired using a Thermo TSQ Endura triple quadrupole MS.","label":[],"Comments":[]}
{"id":3499,"text":"Multiple reaction monitoring (MRM) mode using positive ion mode.","label":[],"Comments":[]}
{"id":3500,"text":"For all compounds, the spray voltage was 4500 V, vaporizer temperature and transfer tube temperature were 400°C and 350°C, respectively.","label":[],"Comments":[]}
{"id":3501,"text":"The CID argon pressure was set to 2.0 mTorr.","label":[],"Comments":[]}
{"id":3502,"text":"The MRM transitions were as previously described (Tolonen et al., 2007; Turpeinen et al., 2005).","label":[],"Comments":[]}
{"id":3503,"text":"For acetaminophen, hydroxyrepaglinide and 4‐hydroxydiclofenac MRM's were m\/z 152 >  m\/z 110, m\/z 469 >  m\/z 246, m\/z 312 >  m\/z 231, respectively.","label":[[4,17,"Drug"],[19,37,"Drug"],[42,61,"Drug"]],"Comments":[]}
{"id":3504,"text":"The instruments were controlled using Thermo Xcalibur 3.0.63 software.","label":[],"Comments":[]}
{"id":3505,"text":"Fifty percent inhibitory concentration (IC   where A = log of concentration of aqueous extract of herb in the incubations.","label":[[0,38,"Parameter"],[79,94,"Extraction process"]],"Comments":[]}
{"id":3506,"text":"The herb extracts were classified as potent, moderate, or weak inhibitor depending on the IC Determination of molar IC   Aqueous extracts of Musa sapientum unripe fruits, Tetracarpidium conophorum seeds, and Allium sativum bulbs did not produce significant inhibition of the CYP isoenzymes investigated at any of the concentrations used, IC Estimated in vitro IC IC Percentage inhibition of the control by herbs with IC Aqueous extract of Mangifera indica stem bark showed weak inhibitory activities on CYP2A6, CYP2C19 and CYP3A4 but exhibited moderate inhibition of CYP1A2, CYP2B6, CYP2C8, CYP2C9, and CYP2D6 (Table 2).","label":[[90,92,"Parameter"],[116,118,"Parameter"],[121,137,"Extraction process"],[141,155,"Herb name"],[163,169,"Herb part"],[171,196,"Herb name"],[197,202,"Herb part"],[208,222,"Herb name"],[223,228,"Herb part"],[275,289,"Target"],[338,340,"Parameter"],[351,359,"Study"],[360,362,"Parameter"],[363,365,"Parameter"],[417,419,"Parameter"],[420,435,"Extraction process"],[439,455,"Herb name"],[456,465,"Herb part"],[503,509,"Target"],[511,518,"Target"],[523,529,"Target"],[567,573,"Target"],[575,581,"Target"],[583,589,"Target"],[591,597,"Target"],[603,609,"Target"]],"Comments":[]}
{"id":3507,"text":"The plant extract displayed 100% inhibition of all the CYP isoenzymes investigated at a dose of 1000 μg\/ml (Figure 1b).","label":[[55,69,"Target"]],"Comments":[]}
{"id":3508,"text":"Picralima nitida seeds aqueous extract demonstrated potent inhibitory activity on CYP2D6, with IC In order to estimate the possibility of in vivo inhibitory potential from the in vitro data, IC Inhibition of cytochrome P450 isoezymes by herbs with IC Drug–drug interaction or herb–drug interaction studies could be conducted as in vitro or in vivo studies, case reports, and human studies using human subjects.","label":[[0,16,"Herb name"],[17,22,"Herb part"],[23,38,"Extraction process"],[82,88,"Target"],[95,97,"Parameter"],[176,184,"Study"],[191,193,"Parameter"],[208,223,"Target"],[248,250,"Parameter"],[276,305,"Study"],[328,336,"Study"],[340,355,"Study"],[357,369,"Study"],[375,388,"Study"]],"Comments":[]}
{"id":3509,"text":"In vitro herb–drug interactions studies are mostly conducted for commonly used herbs to evaluate and predict potentially significant in vivo herb–drug interactions and to help design appropriate in vivo herb–drug interaction studies (Fasinu, Bouic, & Rosenkranz, 2012; Awortwe, Bouic, Masimirembwa, & Rosenkranz, 2013).","label":[[0,39,"Study"],[195,232,"Study"]],"Comments":[]}
{"id":3510,"text":"According to Food and Drug Administration, 2017, in vitro drug–drug interaction (DDI) studies are designed to determine if a drug is a substrate, inhibitor, or inducer of metabolizing enzymes (Phase I or Phase II enzymes), transporter proteins (P‐gp, BCRP, OATP1B1, OATP1B3, OAT, OCT, and MATE) and also to evaluate whether the metabolite of a drug is a substrate or inhibitor of metabolizing enzymes or transporter proteins.","label":[[49,93,"Study"],[245,249,"Target"],[251,255,"Target"],[257,264,"Target"],[266,273,"Target"],[275,278,"Target"],[280,283,"Target"],[289,293,"Target"]],"Comments":[]}
{"id":3511,"text":"These are referred to as metabolism‐based or transporter‐based drug interaction studies.","label":[[25,87,"Study"]],"Comments":[]}
{"id":3512,"text":"Preclinical methods for predicting drug interactions use enzyme sources such as purified CYP450 isoenzymes, immortalized cell lines, recombinant P450 isoenzymes, liver slices, human microsomes, and hepatocyte cultures.","label":[[0,19,"Study"],[89,106,"Target"]],"Comments":[]}
{"id":3513,"text":"Microsomes isolated from human hepatocytes have become the “gold standard” of in vitro experimentation for drug interactions and contain the CYPs in proportion to their in vivo representation.","label":[[78,102,"Study"],[141,145,"Target"]],"Comments":[]}
{"id":3514,"text":"Pooled human liver microsomes were employed in this study to circumvent the large interindividual variability in CYP expression when microsomes from a single individual are used which may produce biased results.","label":[[113,116,"Target"]],"Comments":[]}
{"id":3515,"text":"The N‐in‐one assay method employed in this study allows for rapid screening of many herbs or herbal products for inhibitory potential of major human CYP isoenzymes.","label":[[149,152,"Target"]],"Comments":[]}
{"id":3516,"text":"This may help clinicians and patients to avoid concomitant use of herbs and drugs that may lead to potential or actual HDIs.","label":[],"Comments":[]}
{"id":3517,"text":"Three of the plants studied did not exhibit inhibitory potential on any of the eight major human CYP isoenzymes used even at the highest dose of the extract, that is, aqueous extracts of Musa sapientum unripe fruits, Tetracarpidium conophorum seeds, and Allium sativum bulbs.","label":[[97,111,"Target"],[167,183,"Extraction process"],[187,201,"Herb name"],[202,215,"Herb part"],[217,242,"Herb name"],[243,248,"Herb part"],[254,268,"Herb name"],[269,274,"Herb part"]],"Comments":[]}
{"id":3518,"text":"There are conflicting reports on the inhibitory potential of Allium sativum extracts on CYP isoenzymes.","label":[[61,75,"Herb name"],[88,102,"Target"]],"Comments":[]}
{"id":3519,"text":"This herb was classified by Engdal and Nilsen (2009) as a noninhibitor of CYP3A4 using human c‐DNA baculovirus expressed CYP3A4.","label":[[74,80,"Target"],[121,127,"Target"]],"Comments":[]}
{"id":3520,"text":"Using similar methods, Foster et al.","label":[],"Comments":[]}
{"id":3521,"text":"(2001) reported in vitro inhibition of CYP 2C9, 2C19, 2D6, 3A4\/5, and 3A7 by different types of Allium sativum.","label":[[16,24,"Study"],[39,73,"Target"],[96,110,"Herb name"]],"Comments":[]}
{"id":3522,"text":"In another study, only two water‐soluble components of aged garlic were able to moderately inhibit CYP3A4 (Greenblatt et al., 2006).","label":[[60,66,"Herb name"],[99,105,"Target"]],"Comments":[]}
{"id":3523,"text":"Also, aged garlic extract produced no significant inhibition of CYP isoenzymes in humans (Markowitz, 2003).","label":[[11,17,"Herb name"],[64,78,"Target"]],"Comments":[]}
{"id":3524,"text":"Though we did not report any inhibition of CYP isoenzymes by Allium sativum, the discrepancies in these reports and ours may be due to the extraction procedure, assay method, concentration and type of the extract used and enzyme sources.","label":[[43,57,"Target"],[61,75,"Herb name"]],"Comments":[]}
{"id":3525,"text":"In this study, aqueous extract of oven‐dried Allium sativum bulbs was used.","label":[[15,44,"Extraction process"],[45,59,"Herb name"],[60,65,"Herb part"]],"Comments":[]}
{"id":3526,"text":"There is no conclusive report of a significant in vitro inhibition of CYP isoforms by Allium sativum both from this study and others.","label":[[47,55,"Study"],[70,82,"Target"],[86,100,"Herb name"]],"Comments":[]}
{"id":3527,"text":"Thus, the possibility of Allium sativum aqueous extract in vivo HDIs mediated by CYP isoenzymes may be remote as supported by our study and that of Markowitz (2003).","label":[[25,39,"Herb name"],[40,55,"Extraction process"],[81,95,"Target"]],"Comments":[]}
{"id":3528,"text":"Aqueous extract of Moringa oleifera leaves showed weak inhibition of CYP1A2 and CYP2C9.","label":[[0,15,"Extraction process"],[19,35,"Herb name"],[36,42,"Herb part"],[69,75,"Target"],[80,86,"Target"]],"Comments":[]}
{"id":3529,"text":"This result is similar to the inhibition of CYP1A2 by ethanolic and aqueous extracts of Moringa oleifera leaves reported earlier (Taesotikul et al., 2010).","label":[[44,50,"Target"],[54,84,"Extraction process"],[88,104,"Herb name"],[105,111,"Herb part"]],"Comments":[]}
{"id":3530,"text":"Other studies reported inhibition of CYP3A4 (Ahmmed et al., 2015; Awortwe, 2015; Monera et al., 2008) and CYP2D6 by aqueous and\/or ethanolic extract(s) of M. oleifera leaves (Ahmmed et al., 2015) which were not observed in this study.","label":[[37,43,"Target"],[106,112,"Target"],[116,151,"Extraction process"],[155,166,"Herb name"],[167,173,"Herb part"]],"Comments":[]}
{"id":3531,"text":"The possibility of in vivo inhibition of CYPs 1A2 and 2C9 by aqueous extract of M. oleifera is likely since the IC Stem bark aqueous extract of Mangifera indica moderately inhibited CYP1A2, CYP2B6, CYP2C8, CYP2C9, and CYP2D6 (IC The potential for Mangifera indica stem bark aqueous extract to cause in vivo HDIs specifically with drugs with narrow therapeutic index is supported by the estimated IC Several studies have used Strandell et al.","label":[[41,57,"Target"],[61,76,"Extraction process"],[80,91,"Herb name"],[112,114,"Parameter"],[115,124,"Herb part"],[125,140,"Extraction process"],[144,160,"Herb name"],[182,188,"Target"],[190,196,"Target"],[198,204,"Target"],[206,212,"Target"],[218,224,"Target"],[226,228,"Parameter"],[247,263,"Herb name"],[264,273,"Herb part"],[274,289,"Extraction process"],[396,398,"Parameter"]],"Comments":[]}
{"id":3532,"text":"(2004) methods to predict possibilities of in vivo inhibition of CYP isoenzymes from in vitro data.","label":[[65,79,"Target"],[85,98,"Study"]],"Comments":[]}
{"id":3533,"text":"For example, in vitro study by Sevior et al.","label":[[13,27,"Study"]],"Comments":[]}
{"id":3534,"text":"(2010) predicted the possible absence of in vivo inhibition of CYP 2D6 and 3A4 by black cohosh and aqueous extract of valerian and inhibition of CYP2D6 by goldenseal.","label":[[63,78,"Target"],[82,94,"Herb name"],[99,114,"Extraction process"],[118,126,"Herb name"],[145,151,"Target"],[155,165,"Herb name"]],"Comments":[]}
{"id":3535,"text":"Earlier studies by Gurley et al.","label":[],"Comments":[]}
{"id":3536,"text":"(2005, 2006, 2008) confirmed these predictions.","label":[],"Comments":[]}
{"id":3537,"text":"Strandell et al.","label":[],"Comments":[]}
{"id":3538,"text":"(2004) predicted the likelihood of potent in vivo inhibition of CYP3A4 by hypericum (St John's Wort) preparations; this also confirmed the report of Markowitz et al.","label":[[64,70,"Target"],[74,100,"Herb name"]],"Comments":[]}
{"id":3539,"text":"(2000).","label":[],"Comments":[]}
{"id":3540,"text":"Currently, no study seems to be available on the in vitro or in vivo inhibitory activity of six of the herbs studied—aqueous extracts of Picralima nitida seeds, Gongronema latifolium leaves, Tetracarpidium conophorum seeds, Musa sapientum unripe fruits, Bauhinia monandra leaves, and Alstonia boonei stem bark.","label":[[117,133,"Extraction process"],[137,153,"Herb name"],[154,159,"Herb part"],[161,182,"Herb name"],[183,189,"Herb part"],[191,216,"Herb name"],[217,222,"Herb part"],[224,238,"Herb name"],[239,252,"Herb part"],[254,271,"Herb name"],[272,278,"Herb part"],[284,299,"Herb name"],[300,309,"Herb part"]],"Comments":[]}
{"id":3541,"text":"Our study may be the first report of the in vitro inhibitory potential of these herb extracts.","label":[[41,49,"Study"]],"Comments":[]}
{"id":3542,"text":"Gongronema latifolium and Alstonia boonei may produce in vivo inhibitory activity on CYP1A2, CYP2C19 and CYP3A4 since the converted in vitro IC One of the problems of studying herb–drug interactions is the difficulty in identifying or quantifying the inhibiting components of the complex mixtures of phytochemicals in the herb.","label":[[0,21,"Herb name"],[26,41,"Herb name"],[85,91,"Target"],[93,100,"Target"],[105,111,"Target"],[132,140,"Study"],[141,143,"Parameter"]],"Comments":[]}
{"id":3543,"text":"Because of this, it is difficult to quantify the molar IC  Picralima nitida seem to be the most potent of the nine herbs studied with IC It should be borne in mind that the IC Of the nine aqueous herb extracts evaluated in this study, Picralima nitida, Alstonia boonei, and Mangifera indica showed significant in vitro inhibition of several cytochrome P450 isoenzymes including CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 with potential for significant clinical herb–drug interactions.","label":[[55,57,"Parameter"],[59,75,"Herb name"],[134,136,"Parameter"],[173,175,"Parameter"],[188,209,"Extraction process"],[235,251,"Herb name"],[253,268,"Herb name"],[274,290,"Herb name"],[310,318,"Study"],[341,367,"Target"],[378,384,"Target"],[386,392,"Target"],[394,400,"Target"],[402,408,"Target"],[410,417,"Target"],[419,425,"Target"],[431,437,"Target"]],"Comments":[]}
{"id":3544,"text":"The potent in vitro inhibitory effect of aqueous extract of Picralima nitida on CYP2D6 makes it a candidate for immediate further clinical investigations.","label":[[11,19,"Study"],[41,56,"Extraction process"],[60,76,"Herb name"],[80,86,"Target"],[130,153,"Study"]],"Comments":[]}
{"id":3545,"text":"However, before this is done, caution should be exercised by clinician and patients alike in recommending or coadministering aqueous extracts of Picralima nitida seeds with substrates of CYP2D6.","label":[[125,141,"Extraction process"],[145,161,"Herb name"],[162,167,"Herb part"],[187,193,"Target"]],"Comments":[]}
{"id":3546,"text":"Authors have no conflict of interest to declare.","label":[],"Comments":[]}
{"id":3547,"text":"This study does not involve any human or animal testing.","label":[],"Comments":[]}
{"id":3548,"text":"Click here for additional data file.","label":[],"Comments":[]}
{"id":3549,"text":"Authors would like to appreciate the kind gift of Picralima nitida seeds by Dr James Adetunji Bello, The Chief Medical Director, Oyo state Hospital, Ogbomoso.","label":[[50,66,"Herb name"],[67,72,"Herb part"]],"Comments":[]}
